|D012127||Respiratory Distress Syndrome, Newborn NIH||0.08|
|D055371||Acute Lung Injury NIH||0.08|
There is one clinical trial.
Ideal new treatments for Novel Coronavirus-19 (COVID-19) would help halt the progression disease in patients with mild disease prior to the need for artificial respiration (ventilators), and also provide a rescue treatment for patients with severe disease, while also being affordable and available in quantities sufficient to treat large numbers of infected people. Low doses of Naltrexone, a drug approved for treating alcoholism and opiate addiction, as well as Ketamine, a drug approved as an anesthetic, may be able to interrupt the inflammation that causes the worst COVID-19 symptoms and prove an effective new treatment. This study will investigate their effectiveness in a randomized, blinded trial versus standard treatment plus placebo.
Description: Count of participants initially presenting with mild/moderate disease who progress to requiring advanced oxygenation (high flow nasal canula, non-rebreather, continuous positive airway pressure (CPAP), bilevel positive airway pressure (BIPAP), or intubation)Measure: Progression of oxygenation needs Time: up to 1 month
Description: Count of participants who develop or experience worsened renal failure as defined by RIFLE criteria, a 5-point scale where the categories are labeled: Risk-Injury-Failure-Loss-End stage renal disease, with Risk being the least severe and End stage renal disease being the most severe. The criteria for determination of stage are factors of serum creatinine and urine output. Numbers of participants worsening one or more RIFLE stages will be reported.Measure: Renal failure Time: up to 1 month
Description: Count of participants who develop or experience worsened liver failure as defined by serum transaminases five times normal limitsMeasure: Liver failure Time: up to 1 month
Description: Count of participants who develop cytokine storm as measured by elevated markers of inflammation (elevated D-dimer, hypofibrinogenemia, hyperferritinemia), evidence of acute respiratory distress syndrome (ARDS) measured by imaging findings and mechanical ventilator requirements, and/or continuous fever (≥ 38.1 ° Celsius unremitting)Measure: Cytokine Storm Time: up to 1 month
Description: Count of participants who die from COVID-19Measure: Mortality Time: up to 1 month post hospital discharge
Description: Length of hospital stay in daysMeasure: Length of hospital stay Time: up to 1 month
Description: Count of patients admitted to the ICU at any time during index hospitalizationMeasure: Intensive Care Unit (ICU) admission Time: up to 1 month
Description: Length of ICU stay in daysMeasure: Intensive Care Unit (ICU) duration Time: up to 1 month
Description: Count of participants requiring intubationMeasure: Intubation Time: up to 1 month
Description: Length of intubation, measured in daysMeasure: Intubation duration Time: up to 1 month
Description: Time measured in days from hospital admission to determination patient is stable for dischargeMeasure: Time until recovery Time: up to 1 month
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports